Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Tarlatamab |
| Synonyms | |
| Therapy Description |
Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Tarlatamab | Imdelltra | AMG 757|AMG757|AMG-757|tarlatamab-dlle | CD3 Antibody 119 DLL3 Antibody 10 | Imdelltra (tarlatamab) is a bispecific antibody that targets CD3 on T-cells and delta-like protein 3 (DLL3) expressed by tumor cells, which may lead to cytotoxic killing of Dll3-expressing tumor cells (PMID: 31215500). Imdelltra (tarlatamab) is FDA-approved for use in patients with extensive stage small cell lung cancer who progressed on or after platinum-based chemotherapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07061080 | Phase II | Tarlatamab Fluorouracil + Irinotecan + Leucovorin + Tarlatamab | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab (RAGNAR) | Not yet recruiting | FRA | ESP | 0 |
| NCT07242547 | Phase II | Tarlatamab | Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients (MERLIN) | Not yet recruiting | ESP | 0 |
| NCT05740566 | Phase III | Lurbinectedin Topotecan Amrubicin Tarlatamab | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) | Active, not recruiting | USA | TUR | ROU | POL | NLD | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT06745323 | Phase II | Tarlatamab | A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC (DeLLphi-309) | Recruiting | USA | TUR | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BEL | AUS | ARG | 3 |
| NCT06598306 | Phase I | Tarlatamab | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) (DeLLphi-308) | Recruiting | USA | TUR | POL | ESP | DEU | CHE | BEL | AUS | 2 |
| NCT06814496 | Phase Ib/II | Tarlatamab | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) | Recruiting | USA | 0 |
| NCT06937905 | Phase III | Tarlatamab | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) (TARLANEC) | Not yet recruiting | FRA | 0 |
| NCT04702737 | Phase I | Tarlatamab | A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer | Completed | USA | NLD | GBR | FRA | ESP | BEL | AUT | AUS | 1 |
| NCT07016230 | Phase II | Tarlatamab | Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB) | Recruiting | FRA | 0 |
| NCT05060016 | Phase II | Tarlatamab | A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DNK | DEU | CHE | BEL | AUT | 5 |
| NCT07111507 | Phase II | Tarlatamab | A Study of Tarlatamab for People With Prostate Cancer | Recruiting | USA | 0 |
| NCT06117774 | Phase III | Tarlatamab | Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) (DeLLphi-306) | Recruiting | USA | TUR | SWE | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CHE | BRA | BGR | BEL | AUT | AUS | ARG | 9 |
| NCT03319940 | Phase I | Tarlatamab | Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer | Active, not recruiting | USA | POL | NLD | GBR | FRA | ESP | DEU | CHE | AUT | AUS | 3 |
| NCT06776250 | Phase II | Tarlatamab | Study of How Safe and Effective Tarlatamab is in Brain Cancers | Recruiting | CAN | 0 |
| NCT06788938 | Phase II | Tarlatamab | Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | Recruiting | USA | 0 |
CKB BOOST